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Abstract
Myocarditis and Pericarditis have many virological and immunological causes. This article described the SARS-CoV
involvement to the heart in children and adolescents, also the entity Multisystem Inﬂammatory Syndrome in Children
(MIS-C), a rare but severe consequence of SARS-CoV2 infection. Hong Kong case deﬁnition of MIS-C was listed. The
consensus from overseas experts was that MIS-C should be managed by multidisciplinary team with a structured longterm follow-up to monitor the functioning of various organs and ascertain the prognosis. The side effect mRNA
vaccination causing myocarditis and pericarditis is also concern of paediatricians worldwide. Hong Kong published
local epidemiology of acute myocarditis and pericarditis among adolescents following Comirnaty vaccination, the local
and overseas data were used in ﬁne-tuning the COVID vaccination program in children and adolescents. To prevent
severe and fatal outcome of COVID-19 diseases, it is important to educate the public and to promote COVID-19
vaccination in the community, also to continue monitoring the safety of the available vaccines.
Keywords: COVID-19, SARS-CoV2, Multisystem inﬂammatory syndrome, mRNA vaccination, Myocarditis and
pericarditis

M

yocarditis/pericarditis have many virological
and immunological causes [1,2], both can
occur after SARS-CoV-2 infection alone or as a
consequence of multisystem inﬂammatory syndrome in children (MIS-C) following COVID-19
infection [3,4].

COVID-19 infection can affect different organ
systems, cardiovascular complications is one of the
main concerns, in particular among children with
pre-existing congenital heart diseases [5e7]. Injury
to the myocardium can be resulted from a direct
invasion of the virus or related to an exaggerated
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immune response [4,6,7]. Viral entry via angiotensin-converting enzyme-2 (ACE-2) receptor is
considered to be the mechanism leading to damage
of target cells including cardiomyocytes [8]. Other
reasons causing the myocardial damage can be
related to immune-mediated injury secondary to
excessive cytokine release or T-cell dysregulation,
microvascular damage, endothelial shedding/
dysfunction, and hypoxia-mediated injury resulting
from a thromboembolic phenomenon [9].

Multisystem inﬂammatory syndrome in
children (MIS-C)
MIS-C, also termed Paediatric Inﬂammatory
Multisystem Syndrome Temporally Associated with
SARS-CoV-2 (PIMS-TS), is a severe multisystem inﬂammatory syndrome associated with COVID-19
infection. MIS-C typically presents 2e6 weeks after
exposure to SARS-CoV-2 [10,11]. Patients can present
with a wide range of symptoms and signs, such as
persistent fever, polymorphic rashes, gastrointestinal
symptoms, conjunctivitis, and mucosal changes
[10e12]. There is also severe systemic inﬂammation as
evidenced by the elevation of inﬂammatory markers
(ESR, CRP, ferritin), multiple organ dysfunction, and
cytokine storm (particularly raised IL-6 level) among
these patients. Some children with MIS-C required
intensive care because of hypotension due to acute
myocardial failure, systemic hyperinﬂammation, and
vasodilatation, requiring inotropic support [13,14].
Other signiﬁcant cardiac manifestations, including
coronary dilatation, aneurysms, and arrhythmias,
have also been reported. Troponin level and N-terminal pro-B type natriuretic peptide (NT Pro-BNP)
are useful markers of cardiac involvement and subsequent monitoring. Despite similarities in the clinical
presentation of MIS-C and Kawasaki Disease (KD),
infectious diseases experts considered them to be two
rather different entities [15,16]. Children with MIS-C
were generally older and had much higher levels of
inﬂammatory markers than KD. Patients with KD
were more likely to have rash (96.0% vs. 50.2%;
P < 0.001), conjunctival injection (94.1% vs. 61.8%;
P < 0.001), and coronary artery abnormalities (28.7%
vs. 15.0%; P ¼ 0.006) but less likely to have other cardiovascular outcomes (myocarditis, decreased cardiac
function, mitral regurgitation, pericardial effusion), as
well as gastrointestinal, neurologic, or renal involvement. Patients with MIS-C had elevated CRP and
decreased platelet counts, and lymphocyte nadir
counts compared with patients with COVID-19 and
KD. Patients with MIS-C shock were more likely to
report abdominal pain (77.0% vs. 27.3%; P ¼ 0.003) and
headache (49.2% vs. 0%; P ¼ 0.001), whereas patients

with KD shock syndrome (KDSS) were more likely to
have coronary artery dilatation or aneurysm (63.6%
vs. 17.7%; P ¼ 0.002) and rash (90.9%e48.7%;
P ¼ 0.009). Patients with MIS-C shock had lower
lymphocyte counts (median, 580/mL vs. 1350/mL) and
shorter duration of fever (median, 5 vs. 7 days;
P ¼ 0.020) [16].
Given a growing number of complicated paediatric
COVID-19 cases and the occurrence of MIS-C associated with COVID-19 infection in Hong Kong since
mid-March 2022, expert group meetings with presentation from overseas expert and separate sharing
of clinical experience among colleagues in different
HA Paediatric Departments and private sector who
have managed MIS-C cases in Hong Kong were
hosted at the ChildSim, Simulation Training Centre
of Hong Kong Children's Hospital in April 2022
[17e19]. The special presentation by various hospital
representatives on April 27, 2022 not only facilitated a
fruitful exchange of clinical knowledge and management but also enabled agreeable standardized
local reporting criteria for MIS-C to be established
through reviewing currently available evidence and
different international diagnostic criteria (Table 1)
[20e22]. It was suggested that post-infectious immune dysregulation, an aberrant development of
acquired immunity to SARS-CoV2, is probably the
reason causing MIS-C [14,15,23], but further research
is needed to delineate the pathophysiology.
The treatment goals for MIS-C are to decrease the
systemic inﬂammation, restore the organs’ function,
decrease the mortality and reduce the risk of longterm sequelae such as the neurological complications
[24], development of coronary artery aneurysm, and
cardiac dysfunction. However, the optimal therapeutic strategy is still uncertain as current studies still
did not ﬁnd evidence suggesting the outcomes
recovered from MIS-C being differed after treatment
with 1) intravenous immunoglobulin (IVIG) alone, 2)
with IVIG plus glucocorticoids, or 3) with only glucocorticoids [25]. The consensus from overseas experts was that MIS-C should be managed by a
multidisciplinary team with a structured long-term
follow-up to monitor the functioning of various organs and ascertain the prognosis [24,26e28].

Post-COVID vaccine myocarditis
In Hong Kong, the COVID-19 vaccination program
started on February 26, 2021. The available vaccines
for public use include the CoronaVac (an inactivated
virus vaccine developed by Sinovac) and the Comirnaty (BNT162b2 mRNA vaccine co-developed by
BioNTech and Pﬁzer and manufactured and distributed in China by Fosun Pharma). The Food and
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Table 1. Hong Kong case deﬁnition of multisystem inﬂammatory
syndrome in children (MIS-C).
All six criteria need to be met:
1. Children and Adolescents from 0 to 17 years old.
2. Evidence of SARS-CoV-2 infection: documented [1] RAT þ ve,
or [2] PCR þ ve, or [3] positive SARS-CoV2 Ab or [4] contact
history with an individual with SARS-CoV-2 infection.
3. Fever for 24 hours.
4. Two or more organs involvement:
 Gastrointestinal System: e.g. Vomiting, diarrhoea
 Hepatitis, pancreatitis
 Central Nervous System e.g. Change in conscious state,
seizures, meningitis
 Respiratory: e.g. Pneumonia, pleural effusion
 Dermatological: e.g. Mucosal changes (conjunctivitis, red
and cracked lips, strawberry tongue), erythematous
skin rashes
 Coagulopathy: e.g. Platelets and white blood cell
abnormalities, deranged clotting proﬁle, raised D-dimer
level
 Cardiovascular system: e.g. Pericarditis, myocarditis,
coronary artery dilatation, shock
 Renal system: e.g. acute kidney injury
5. Evidence of inﬂammation with elevation in any i
nﬂammatory markers: ESR, CRP, CK, Troponin, Ferritin,
NT-ProBNP
6. Infection or inﬂammation cannot be explained by other
pathogens.
RAT, rapid antigen test; PCR, polymerase chain reaction; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; CK,
creatinine kinase; NT ProBNP, N-terminal pro-B type natriuretic
peptide; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Ab, antibody.

Health Bureau, Hong Kong SAR Government, lowered the age limit for receiving the Comirnaty vaccine to 12 years on June 14, 2021 [29]. Since April
2021, there have been reports that myocarditis and
pericarditis have occurred in adolescents and young
adults after mRNA COVID-19 vaccinations internationally [30e32], which is an uncommon association
as it is known to be a rare association following
smallpox vaccination (around 12e16.1 per million
vaccinated individuals) [33].
Between June 14, 2021 and September 4, 2021, 33
cases of myocarditis and pericarditis following
Comirnaty vaccination were identiﬁed using the
criteria created by the Cardiovascular Injury-Coalition for Epidemic Preparedness Innovations (CEPI)
and the Brighton Working Group [34]. Among these
adolescents, 29 (87.88%) were male, and 4 (12.12%)
were female, with a median age of 15.25 years. 27
(81.82%) and 6 (18.18%) cases developed acute
myocarditis and pericarditis after receiving the
second and ﬁrst dose, respectively. All patients have
a relatively mild course and required conservative
management only. The overall incidence of acute
myocarditis and pericarditis was 18.52 (95% conﬁdence interval [CI], 11.67e29.01) per 100,000 persons
vaccinated. The incidence after the ﬁrst and second
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doses were 3.37 (95% CI, 1.12e9.51) and 21.22 (95%
CI, 13.78e32.28) per 100,000 persons vaccinated,
respectively. Among male adolescents, the incidence after the ﬁrst and second doses were 5.57
(95% CI, 2.38e12.53) and 37.32 (95% CI, 26.98e51.25)
per 100,000 persons vaccinated.
An increase in the incidence of myocarditis and
pericarditis was found following the second dose of
mRNA vaccine, especially among the young male
adolescents, which concurred with the observation
in other parts of the world [29,35]. Balancing the risk
of myocarditis and the beneﬁt of protecting against
severe COVID-19 infection, adolescents aged 12e17
years old in Hong Kong were recommended by JSCEAP (the Joint Scientiﬁc Committee on Vaccine
Preventable Diseases (SCVPD) and the Scientiﬁc
Committee on Emerging and Zoonotic Diseases
(SCEZD) under the Centre for Health Protection of
the Department of Health (DH) joined by the Chief
Executive's expert advisory panel (EAP)) to receive
only one dose of the BNT162B2 instead of two doses
since September 15, 2021 [36]. A cohort study
conﬁrmed that the adopted single-dose regimen
was associated with a signiﬁcant reduction in the
risk of developing myocarditis among adolescents
in a setting with no evidence of local transmission
[37]. Another mouse-model study also demonstrated that administering the BNT162b2 intravenously induced acute myocarditis, which has raised
the attention of the JSC-EAP [38]. The JSC-EAP thus
recommended that the option for intramuscular
injection of the Comirnaty vaccine at the mid-anterolateral thigh should be considered, especially for
children and adolescents [37]. A case-control study
demonstrated the increased risk for carditis after
using the mRNA BNT162b2 vaccine but not the
inactivated COVID vaccine CoronaVac [39].
The pathophysiology of mRNA vaccine-induced
myocarditis is yet to be unraveled. The autopsy
report from a case from Korea who died from mRNAvaccine-induced myocarditis demonstrated that it is
histologically different from viral or immune-mediated myocarditis. The mRNA vaccine-induced
myocarditis was predominantly characterized by
neutrophil and histiocyte inﬁltrates, rather than
lymphocytes. Furthermore, single-cell necrosis of
myocytes without inﬂammation was at multiple sites
throughout the atria and multiple contraction band
necrosis predominantly in the left ventricle [40].
More studies will be needed to deﬁne the pathophysiology of mRNA vaccine-induced myocarditis.
At the beginning of the Omicron-variant outbreak
in December 2021, emerging scientiﬁc data suggested
that two doses of the Comirnaty vaccine administered
at a longer interval greater than 8 weeks have a lower
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risk of myocarditis and pericarditis when compared to
receiving at a shorter interval and without compromising the immune responses [41]. On December 23,
2021, the JSC-EAP recommended that adolescents
aged 12 to 17 receive two doses of the Comirnaty
vaccine at least 12 weeks apart [42]. Between
September 15, 2021 when JSC-EAP recommended
one dose of mRNA vaccine and December 23, 2021
when JSC-EAP modiﬁed the recommendation back to
2 doses, there were only 6 reported cases of myocarditis (2 deﬁnite, 3 probable, and 1 possible) and 1
probable perimyocarditis. As Hong Kong faced the
ﬁfth wave of the COVID-19 outbreak due to the Omicron variant in February 2022, the JSC-EAP further
recommended shortening the time interval between
the two doses of receiving the Comirnaty vaccines
from 12 weeks to 8 weeks for children and adolescents
aged 5e17 years to provide adequate protection
against COVID-19-related severe complications.
Third dose mRNA BNT162b2 vaccine can also be
considered for adolescents aged 12e17 years old at an
interval of 5 months after the second dose. In addition,
the JSC-EAP continued recommending intramuscular injection of the Comirnaty vaccine at the midanterolateral thigh, especially for male children and
adolescents, to reduce the risk of vaccine-related
myocarditis [43]. Since February 2022, there are 6 reported cases of adolescents (3 with myocarditis, 1 with
perimyocarditis, and 2 with pericarditis) developing
myocarditis and pericarditis after receiving the third
dose mRNA BNT162b2 vaccine. In a recent population-based study conducted in the UK, it is also
observed that there is also an increased risk of
myocarditis following sequential doses of the
BNT162b2 vaccine, including the third dose, in males
<40 years old. Yet the overall risk remained to be small
[44]. Another study from Israel focusing on military
personnel showed that the incidence of myocarditis
observed one week after receiving the third dose [3.17
(95% CI, 0.64e6.28) per 100,000 vaccines] was lower
than observed a week after a second dose of the vaccine in a similar Israeli military population (5.07 per
100,000 vaccines) [45]. Therefore, continued surveillance for any increased risk of myocarditis among
Hong Kong adolescents will be needed.

Conclusion
The COVID-19 global pandemic was declared on
March 11, 2020 by World Health Organization, and
the COVID-19 vaccines were available around one
year after the pandemic. While there is mRNA
vaccine-related myocarditis, most of these are clinically mild without signiﬁcant cardiac dysfunction or
long-term effects. Only by vaccination can we

effectively prevent the severe and fatal outcomes of
COVID-19. Until a signiﬁcant proportion of the
population has been protected from proper vaccine
coverage, our society cannot return to its normalcy.
Therefore, it is crucial to educate the public, promote vaccination in the community and continue
monitoring the safety of the available vaccines.
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